Peginterferon-alfa

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024
Biotechnology, Pharmaceutical, AIDS, Health, COVID-19, Infectious Diseases, Health Technology, Clinical Trials, Infection, Bangladesh Technical Education Board, RSV, CHB, Influenza, Peginterferon-alfa, HIV Vaccine Trials Network, GSK, Research, Investment, AASLD, HDV, MBA, Cirrhosis, HHS, Administration, Conditional sentence, Hepatology, RNA, Respiratory syncytial virus, ASPR, COVID, Patient, Family, HCMV, Bill, Development, HIV, Pharmaceutical industry

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Complete 24-week treatment data for 30 participants per regimen is expected in the fourth quarter of 2024.
  • The MARCH Part B trial is ongoing with 48-week end of treatment data expected in the fourth quarter of 2024.
  • Revenues: Total revenues for the quarter ended December 31, 2023 were $16.8 million compared to $49.4 million for the same period in 2022.

Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023

Retrieved on: 
Monday, November 13, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Hepatology, INSERM, Immunity, Interferon, Immune system, ALT, HDV, HBsAg, AASLD, Clinical trial, Viral hepatitis, EOT, Patient, Small RNA, Abstract, Week, Monoclonal antibody, Liver, Auckland City Hospital, CHB, University, Peginterferon-alfa, CHD, APHP, Hepatitis, Vir, RNA, Vaccine, Pharmaceutical industry, Communications satellite, Treatment, Medicine

To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.

Key Points: 
  • To date, no participants receiving the combination therapy or VIR-3434 monotherapy have experienced ALT elevations relative to their baseline.
  • “Chronic hepatitis delta is the most aggressive form of viral hepatitis.
  • Vir will host an investor conference call to discuss the Phase 2 CHD & CHB AASLD data at 1:45 p.m. Pacific Time / 4:45 p.m. Eastern Time on November 13th.
  • A live webcast will be available on https://investors.vir.bio and will be archived on www.vir.bio for 30 days.

New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

Retrieved on: 
Wednesday, February 8, 2023
SARS-COV-2, Toronto, HDV, Vaccine, SARS-CoV-2, Ottawa Hospital Research Institute, NEJM, Hospital, Toronto Centre, Patient, Vaccination, Safety, Liver disease, Pontifical Catholic University of Campinas, Risk, Incidence, Clinical trial, RNA, Interim, University, The New England Journal of Medicine, PALO, Mortality, University of Toronto, Hepatitis, Associate, Death, Manuscript, Antibody, MPH, Peginterferon-alfa, Eiger, COVID-19, ISCB Senior Scientist Award, Doctor of Philosophy, Pharmaceutical industry, Medicine, MD

PALO ALTO, Calif., Feb. 8, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine (NEJM). The study, which evaluated newly diagnosed outpatients with mild-to-moderate COVID-19, found that among predominantly vaccinated participants with COVID-19, a single-dose treatment with Eiger's investigational agent, peginterferon lambda, resulted in significantly decreased clinical events. The manuscript titled "Effect of Early Treatment with Pegylated Interferon Lambda among COVID-19 Patients" will be published in the February 9, 2023 issue of NEJM and follows the topline safety and efficacy data announced March 17 2022.

Key Points: 
  • The treatment effect for peginterferon lambda was more pronounced in patients who were treated within 3 days of symptom onset.
  • Incidence of any treatment emergent adverse events was similar between peginterferon lambda and placebo groups, which were primarily injection site reactions.
  • "We have over 100,000 peginterferon lambda syringes readily available with additional manufacturing intermediates to support a capacity of >10 million units if needed.
  • In the context of our ongoing portfolio prioritization process, we continue to explore opportunities for ex-US emergency use of peginterferon lambda for COVID-19."

DEADLINE ALERT for EIGR, TSP, and UIS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, January 9, 2023
Eiger, COVID-19, EUA, Law, FDA, Defendant, Suite, Complaint, Peginterferon-alfa, Investment, Mail, Holding company, Risk management, Unisys, Hydron

LOS ANGELES, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

Deadline Alert: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Notifies Eiger BioPharmaceuticals, Inc. (EIGR) Investors of Class Action and Encourages Investors to Actively Participate

Retrieved on: 
Monday, January 9, 2023
Legal, Professional Services, COVID-19, Peginterferon-alfa, Person, EUA, EAU, Court, FDA, Complaint, Eiger

Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/eigr .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/eigr .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements, and failed to disclose material adverse facts about the Company’s business, operational, and compliance policies.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

EIGR IMPORTANT DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important January 9 Deadline in Securities Class Action – EIGR

Retrieved on: 
Sunday, January 8, 2023
Titan, Food, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, Peginterferon-alfa, EUA, Court, Advertising, Eiger, Class, I-Space (Chinese company), Security (finance), Insurance, Tobacco

WHAT TO DO NEXT: To join the Eiger class action, go to https://rosenlegal.com/submit-form/?case_id=9654 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Eiger class action, go to https://rosenlegal.com/submit-form/?case_id=9654 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Eiger BioPharmaceuticals Class Action Deadline: Submit Your Losses to Johnson Fistel

Retrieved on: 
Wednesday, January 4, 2023
COVID-19, EUA, LLP, Learning, Eiger, Court, Peginterferon-alfa, SAN, FDA, Tobacco

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) --  Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) (“Eiger” or the “Company”).

Key Points: 
  • SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) --  Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) (“Eiger” or the “Company”).
  • The class action is on behalf of shareholders who purchased Eiger securities between March 10, 2021 and October 4, 2022, both dates inclusive (the “Class Period”).
  • Investors are hereby notified that they have until January 9, 2023 to move the Court to serve as lead plaintiff in this action.
  • An investor's ability to share any potential future recovery of the Eiger class action lawsuit is not dependent upon serving as lead plaintiff.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vintage Wine, Eiger, Unisys, and Rent and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, January 4, 2023
EBITDA, RTR, Vintage Wine, Registration statement, Peginterferon-alfa, Growth, Defendant, Wine, Unisys, UIS, P.C, Jewellery, News, Mortality, FDA, VWE, Incidence, COVID, Communication, Lilliput Kidswear, COVID-19, Form, Prospectus, NYSE, EUA, Therapy, IPO, Hospital, Disease, Register, Rent the Runway, Press release, Patient, Class, Renewable energy, Pharmaceutical industry, Audit

On September 13, 2022, Vintage Wine announced its financial results for fiscal year 2022.

Key Points: 
  • On September 13, 2022, Vintage Wine announced its financial results for fiscal year 2022.
  • Throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.
  • On this news, the Company’s stock fell as much as 49% during intraday trading on November 8, 2022, thereby injuring investors.
  • For more information on the Rent the Runway class action go to: https://bespc.com/cases/RENT

EIGER BIOPHARMACEUTICALS, INC. (NASDAQ: EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIG

Retrieved on: 
Tuesday, January 3, 2023
Food, Emergency Use Authorization, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, District court, News, Peginterferon-alfa, Patient, EUA, Court, Investment, FDA, Therapy, The Legal 500, Labour government, Advertising, Eiger, Pharmaceutical industry, Renewable energy, Security (finance)

NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Northern District of California and alleges violations of the Securities Exchange Act of 1934.
  • Eiger is a commercial-stage biopharmaceutical company that focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

DEADLINE ALERT for EIGR, TSP, and UIS: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Tuesday, January 3, 2023
Complaint, COVID-19, Peginterferon-alfa, Suite, EUA, Defendant, Investment, FDA, Eiger, Law, Mail, Holding company, Risk management, Unisys, Hydron

LOS ANGELES, Jan. 03, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Jan. 03, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles